Inotek Pharmaceuticals Corp. (ITEK) Earns Buy Rating from HC Wainwright
Separately, Piper Jaffray Cos. reissued a buy rating and issued a $24.00 target price on shares of Inotek Pharmaceuticals Corp. in a research report on Tuesday, August 16th.
Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) opened at 6.95 on Monday. The company’s 50 day moving average price is $7.76 and its 200 day moving average price is $8.06. The stock’s market cap is $187.17 billion. Inotek Pharmaceuticals Corp. has a 12 month low of $5.81 and a 12 month high of $12.41.
Several hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN acquired a new stake in shares of Inotek Pharmaceuticals Corp. during the third quarter valued at approximately $101,000. Panagora Asset Management Inc. purchased a new position in Inotek Pharmaceuticals Corp. during the third quarter worth about $114,000. Oxford Asset Management purchased a new position in Inotek Pharmaceuticals Corp. during the second quarter worth about $118,000. Citadel Advisors LLC purchased a new position in Inotek Pharmaceuticals Corp. during the second quarter worth about $126,000. Finally, Rhumbline Advisers purchased a new position in Inotek Pharmaceuticals Corp. during the second quarter worth about $134,000. Institutional investors own 73.59% of the company’s stock.
About Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Stock Ratings for Inotek Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corp. and related stocks with our FREE daily email newsletter.